[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bausch & Lomb Incorporated\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,39,62,83,106,127,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":14,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100602831","phase-2-a-study-evaluating-the-safety-and-efficacy-of-a-fixed-dose-combination-for-dry-eye-disease-100602831",false,"NCT07128628","A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease","A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast\u002FPerfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease","Inclusion Criteria:\n\nThis study will include subjects who meet all of the following inclusion criteria:\n\n* Voluntarily provide written informed consent\n* ≥18 years of age\n* Subject-reported history of DED OU for at least 6 months\n* Same eye satisfies the criteria for dry eye signs at both screening and baseline\u002Frandomization\n* The criteria for dry eye symptoms are met at both screening and baseline\u002Frandomization\n* As needed (PRN) or scheduled use of non-prescription (OTC) artificial tear, gels, or lubricants for symptoms of dry eye within the past 30 days\n* Able and willing to follow instructions, including participation in all trial assessments and visits\n\nExclusion Criteria:\n\nThis study will exclude subjects who meet any of the following exclusion criteria (Note: Ocular exclusion criteria are relevant to both eyes, such that meeting a criterion in either eye excludes the subject from the study):\n\n* Known allergy or sensitivity to any study treatment (or any of its components)\n* Best-corrected visual acuity (BCVA) of 0.7 logarithm of the minimum angle of resolution (logMAR) or worse (50 Early Treatment Diabetic Retinopathy Study \\[ETDRS\\] letters; Snellen equivalent score of 20\u002F100 or worse) at Visit 1 (Screening) or Visit 2 (baseline\u002Frandomization)\n* Any clinically significant (CS) ocular surface slit-lamp findings at Visit 1 (Screening) or Visit 2 (baseline\u002Frandomization), or findings that may interfere with trial parameters in the opinion of the Investigator.\n* Use of any of any ocular therapies within 30 days.\n* Unable or unwilling to stop current topical dry eye treatments\n\nAdditional criteria per protocol","ALL","18 Years",{"count":19,"type":20},423,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2",[25],"Dry Eye Disease","RECRUITING","2026-03-11",{"date":29,"type":30},"2026-03-13","ACTUAL",{"date":32,"type":30},"2025-10-24",{"date":34,"type":20},"2026-11",{"name":36,"class":37},"Bausch & Lomb Incorporated","INDUSTRY",32,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":4},"100624658","phase-2-a-study-to-evaluate-the-use-of-topical-ocular-bl1332-for-the-management-of-postoperative-ocular-pain-following-photorefractive-keratectomy-100624658","NCT07412496","A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy","A Randomized, Vehicle-Controlled, Double-Masked, Parallel-Group Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy","Inclusion Criteria:\n\n1. Male or female 18 to 58 years of age, inclusive.\n2. Scheduled to undergo PRK surgery and considered to be a good candidate per the Investigator's discretion.\n3. Provide written informed consent (signed and dated informed consent form \\[ICF\\]) using the Institutional Review Board (IRB)-approved ICF prior to any study-related procedures.\n4. Able to read, understand, and voluntarily sign the ICF and, if applicable, provide written authorization per local privacy regulations.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded from this study. All criteria are evaluated at Screening unless otherwise specified.\n\n1. Women of childbearing potential or non-vasectomized males with partners of childbearing potential are not eligible unless they are using an effective method of contraception and agree to use an effective method of contraception until at least 30 days after study treatment.\n\n   a. Male who is unwilling to agree to use at least 1 medically accepted form of birth control with female partner of childbearing potential.\n2. Participation in a clinical trial within 30 days prior to Screening.","58 Years",{"count":48,"type":20},123,[23],"This is a multicenter, double-masked study to evaluate the use of Topical Ocular BL1332 for the management of post-operative pain after Photorefractive Keratectomy (PRK) surgery.",[52],"Pain, Postoperative","NOT_YET_RECRUITING","2026-02-12",{"date":56,"type":30},"2026-02-17",{"date":58,"type":20},"2026-04",{"date":60,"type":20},"2027-02",{"name":36,"class":37},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100621965","a-study-to-investigate-the-safety-and-effectiveness-of-the-technolas-teneo-317-model-2-excimer-laser-for-laser-in-situ-keratomileusis-lasik-surgery-to-treat-myopia-or-myopic-astigmatism-100621965","NCT07377474","A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism","A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism With Sphere Between 0.00D and -1.00D","Inclusion Criteria:\n\n1. Are 22 years of age or older.\n2. Have read, understood, and signed an ICF.\n3. Have demonstrated stable refraction (i.e., a change of ≤ ± 0.5 D in sphere and cylinder) for a minimum of 12 months prior to surgery verified by consecutive refractions, medical records or prescription history.\n4. Have myopic refractive error with or without astigmatism; sphere 0.00 D up to -1.00 D, cylinder between 0.00 D and -3.00 D; with a manifest refraction spherical equivalent (MRSE) between -.0375 D and -2.50 D.\n5. Wears distance correction or has a need for distance correction.\n6. Have manifest, distance best spectacle corrected visual acuity (BSCVA) of 20\u002F25 (logMAR 0.1) or better in an operative eye.\n7. Have equal to or less than 0.50 D spherical equivalent (SE) difference between cycloplegic and manifest refractions at Visit 1 (Pre-operative).\n8. Have normal corneal topography as determined by the Investigator.\n9. Anticipated postoperative stromal thickness of at least 350 microns.\n10. Have discontinued use of contact lenses for at least 2 weeks (for hard or toric lenses) or 3 days (for soft contact lenses) prior to the pre-operative examination, and through the day of surgery.\n11. All contact lens wearers must demonstrate a stable refraction (within ± 0.5 D), as determined by MRSE, on two consecutive examinations at least 1 week apart, in an eye to be treated and the axis of cylinder should not differ by more than 15 degrees from the baseline cycloplegic refraction.\n12. Agree to emmetropia correction for each treated eye\n13. Have the ability to lie flat without difficulty.\n14. Are willing and able to comply with the schedule for all post-surgery follow-up visits.\n\nExclusion Criteria:\n\n1. Subjects for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in treatment depth less than 250 microns from corneal endothelium.\n2. Acute or chronic disease or illness that would increase operative risk or confound the results of the study (e.g., dry eye, cataract, immuno-compromise, rheumatoid arthritis, clinically significant atopic disease, acne rosacea, autoimmune disease, endocrine disorders, lupus, systemic connective tissue disease, diabetes, or severe atopic disease).\n3. Ocular conditions that may predispose the subject to future complications, including but not limited to:\n\n   * History or evidence of retinal vascular disease\n   * History or evidence of active corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis) in either eye.\n   * History of or evidence of glaucoma or glaucoma suspect (e.g., IOP \\> 21 mmHg).\n4. Eyes for which the baseline manifest subjective refraction exhibits a difference greater than 0.50 D in sphere power, or a difference greater than 0.50 D in cylinder power, or a difference in cylinder axis of more than 15 degrees compared to the baseline cycloplegic subjective refraction. For manifest cylinder of less than 0.50 D, the difference in cylinder axis will not be taken into consideration.\n5. Subjects for whom the pre-operative assessment of the cornea indicates that one or both eyes are not suitable candidates for treatment based upon the Investigator's medical judgment.\n6. Have evidence of retinal vascular disease.\n7. Have a history of or have active corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis, etc.) in either eye.\n8. Have a known sensitivity to any study medication.\n9. Have central corneal scars affecting visual acuity or unstable keratometry with irregular mires in an eye considered for eligibility.\n10. Presence of keratoconus, subclinical or forme fruste keratoconus, corneal dystrophy, unstable central keratometry readings with irregular mires, or other corneal irregularity (e.g., irregular astigmatism).\n11. Had previous intraocular or corneal surgery in an eye considered for eligibility that might confound the outcome of the study or increase the risk to the subject.\n12. Use chronic medications by any administration route that may increase risk to the subject or may confound the outcome of the study, including those known to affect wound healing (e.g., corticosteroids, antimetabolites, etc.).\n13. Are taking medications contraindicated with LASIK such as isotretinoin (Accutane) or amiodarone hydrochloride (Cordarone).\n14. Are known to be pregnant, lactating, or who plan to become pregnant during the course of the study.\n15. Have known sensitivity to medications used for standard LASIK.\n16. Have the presence of systemic disease likely to affect wound healing, e.g., autoimmune disease, systemic connective tissue disease, diabetes, or severe atopic disease.\n17. Are participating in any other ophthalmic clinical trial within 30 days of screening or during this clinical trial.\n18. Have an ocular muscle disorder including a strabismus or nystagmus, or other disorder affecting fixation.\n19. Have a history of or evidence of glaucoma or are a glaucoma suspect.\n20. Eyes with mesopic pupil size \\> 7.0 mm.\n21. Have a Schirmer's pre-operative test without anesthesia \\\u003C 4 mm\u002F5 minutes","22 Years",{"count":38,"type":20},[72],"NA","This will be a multicenter, prospective, open label, non-randomized, single arm study evaluating the safety and effectiveness of the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser when used in LASIK surgery to treat myopia or myopic astigmatism. One or both eyes of a subject may be treated so long as both eyes meet all inclusion\u002Fexclusion requirements.",[75],"Myopic Astigmatism","2026-01-26",{"date":78,"type":30},"2026-01-30",{"date":58,"type":20},{"date":81,"type":20},"2027-09",{"name":36,"class":37},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100520705","ic-8-apthera-iol-new-enrollment-post-approval-study-100520705","NCT06060041","IC-8 Apthera IOL New Enrollment Post Approval Study","Inclusion Criteria:\n\n* 22 years of age or older, any race and any gender;\n* Posterior capsule opacification (PCO) requiring treatment in the IC-8 Apthera IOL eye\n* Able to comprehend and have signed a statement of informed consent;\n* Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visits;\n* Clear intraocular media in both eyes;\n* Preoperative corneal astigmatism ≤1.5 D in the IC-8 Apthera IOL eye prior to IC-8 Apthera implantation;\n* Prior IC-8 Apthera IOL implantation in one eye and a monofocal\u002Fmonofocal toric IOL in the other eye in accordance with the directions for use (DFU) for each IOL.\n\nExclusion Criteria:\n\n* Pharmacologically dilated pupil size less than 7.0 mm in the IC-8 Apthera IOL eye;\n* Irregular astigmatism in either eye;\n* History of retinal disease;\n* Active or recurrent anterior segment pathology;\n* Presence of ocular abnormalities;\n* Diagnosis of dry eye in which patients are unable to maintain eye comfort or adequate vision even with dry eye treatment;\n* Previous corneal or intraocular surgery, except cataract surgery;\n* History of ocular trauma or ocular conditions expected to require retinal laser treatment or other surgical intervention;\n* Acute, chronic or uncontrolled systemic disease that would, in the opinion of the investigator, confound the outcomes of the study;\n* Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with hormonal fluctuation that could lead to refractive changes and dry eye;\n* Concurrent participation or participation in any clinical trial up to 30 days prior to the first visit in the study.\n* Subjects who plan to be traveling, relocating or otherwise unavailable to attend any of the visits",{"count":90,"type":20},435,"OBSERVATIONAL","The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.",[94,95,96],"Cataract","Presbyopia","Posterior Capsule Opacification","2026-01-09",{"date":99,"type":30},"2026-01-12",{"date":101,"type":30},"2023-09-08",{"date":103,"type":20},"2027-09-30",{"name":36,"class":37},14,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100576430","revive-toric-rwe-study-100576430","NCT06785194","Revive Toric RWE Study","Samfilcon B Custom Toric Lens Real-World Observational Study","Inclusion Criteria:\n\n1. Be 18 years or older on the date the ICF is signed\n2. Have the capacity to read, understand, and provide written voluntary informed consent\n3. Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings\n4. Have no active ocular disease or allergic conjunctivitis\n5. Not be using any topical ocular medications\n6. Be willing and able to follow instructions\n7. Have signed a statement of informed consent\n8. Be an experienced soft contact lens wearer (have previously used soft contact lenses)\n9. Meet the indications per the Instructions for Use (IFU) and have a suitable prescription for treatment with the device\n\nExclusion Criteria:\n\n1. Is participating in another research study\n2. Is considered by the Investigator to not be a suitable candidate for participation\n3. Is not eligible for treatment with the study lens per the IFU (contraindicated)\n4. Has had previous ocular surgery\n5. Is taking\u002Fusing ocular, systemic, or topical medications that, in the Investigator's opinion, could potentially affect ocular physiology or lens\u002Fsolution performance",{"count":114,"type":20},30,"This is a post-market observational clinical investigation. The objective of this observational study is to evaluate the visual performance and HCP satisfaction of REVIVE samfilcon B custom toric contact lenses.",[117],"Astigmatism","2025-11-26",{"date":120,"type":30},"2025-11-28",{"date":122,"type":20},"2026-05",{"date":124,"type":20},"2026-07",{"name":36,"class":37},3,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":146,"locationsCount":4},"100563621","effectiveness-and-safety-of-the-teneo-317-model-2-excimer-laser-to-treat-myopia-with-or-without-astigmatism-by-transepithelial-photorefractive-keratectomy-100563621","NCT06618547","Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy","A Study to Investigate the Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy","Inclusion Criteria:\n\n1. 22 years of age or older at the time of the pre-operative examination.\n2. Best distance corrected visual acuity (BCDVA) 20\u002F25 or better in the study eye\n3. Difference between manifest refractive spherical equivalent (MRSE) and the cycloplegic refraction of ≤ 0.75 D in the study eye.\n4. Stable refraction (i.e., a change of ≤ 0.50 D in MRSE) for a minimum of 12 months before surgery, as verified by consecutive refractions, medical records, or prescription history.\n5. Agree to discontinue contact lenses for at least two weeks (for rigid or toric lenses) or three days (for soft contact lenses) before the first refraction to establish stability and through the day of surgery.\n6. A stable refraction (within ± 0.50 D) after discontinuation of contact lens(es), as determined by MRSE between two consecutive examinations at least one week apart.\n7. Normal corneal topography per the investigator in the study eye.\n8. Anticipated postoperative stromal thickness of at least 350 microns.\n9. Ability to lie flat without difficulty.\n10. Willing and able to read, understand, and sign a written informed consent form (ICF)\n11. Willing and able to comply with the schedule for all post-surgery follow-up visits.\n12. Pre-operative myopic refractive error with sphere component from -0.25 D to -8.00 D in each operative eye, with or without cylinder from 0.00 D to -3.00 D, based on the manifest refraction with treated MRSE of -0.25 D to -9.50 D.\n\nExclusion Criteria:\n\n1. Acute or chronic disease or illness that would increase operative risk or confound the results of the study (e.g., dry eye, cataract, immuno-compromise, rheumatoid arthritis, clinically significant atopic disease, acne rosacea, autoimmune disease, endocrine disorders, lupus, systemic connective tissue disease, diabetes, or severe atopic disease).\n2. Use of medications that may increase risk to the subject or may confound the outcome of the study, including those known to affect wound healing (e.g., systemic corticosteroids, antimetabolites)\n3. Ocular conditions that may predispose the subject to future complications, including but not limited to:\n\n   1. Evidence or history of retinal vascular disease\n   2. History or evidence of active corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis) in either eye.\n   3. History of or evidence of glaucoma or glaucoma suspect (e.g., IOP \\> 21 mmHg).\n4. Previous intraocular or corneal surgery in an eye considered for eligibility that might confound the study's outcome or increase the subject's risk.\n5. An increased risk for developing strabismus post-treatment or an ocular muscle disorder (e.g., strabismus or nystagmus) affecting fixation.\n6. Known sensitivity to any study medications (e.g., used during TransEpi PRK procedure and postoperative care).\n7. Central corneal scars affecting visual acuity.\n8. Presence of keratoconus, subclinical or forme fruste keratoconus, corneal dystrophy, or other corneal irregularity (e.g., irregular astigmatism).\n9. Presence of visually significant or progressive cataract in an eye considered for eligibility.\n10. Actively taking medications contraindicated with TransEpi PRK, such as isotretinoin (Accutane®) or amiodarone hydrochloride (Cordarone®).\n11. Cardiac pacemaker, implanted defibrillator, or another implanted electronic device.\n12. Pregnant, lactating, or subjects who plan to become pregnant during the study.\n13. Participation in any other clinical trial within 30 days of screening or during this clinical trial.14. Subjects for whom the pre-operative assessment of the cornea\u002F eyes indicates that one or both eyes are not suitable candidates for treatment based upon the investigator's medical judgment.\n\n15\\. Treated eye with mesopic pupil size \\> 7.0 mm.",{"count":135,"type":20},140,[72],"A Study to Investigate the Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia with or without Astigmatism by Transepithelial Photorefractive Keratectomy",[139],"Myopia","2025-06-13",{"date":142,"type":30},"2025-06-15",{"date":144,"type":20},"2025-11",{"date":34,"type":20},{"name":36,"class":37},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":151,"conditions":159,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},"100539578","a-study-to-evaluate-the-safety-and-efficacy-of-the-bausch--lomb-myopia-control-lens-for-the-correction-of-myopic-ametropia-and-slowing-the-progression-of-myopia-in-children-100539578","NCT06305663","A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children","A Multi-center, Randomized, Parallel, Bilateral, Investigator-masked Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children","Inclusion Criteria:\n\n1. Male or female aged 8 to 12 years plus 11 months old on the date the Informed Assent and Parental or Guardian Informed Consent are signed and have capacity to provide voluntary informed consent.\n2. Subject must meet the following determined by cycloplegic subjective refraction in both eyes at screening:\n\n   1. Spherical Equivalent Refractive Error (SERE): between -0.75 D and -4.00 D, inclusive.\n   2. Astigmatism: ≤ -0.75 D. c. Anisometropia: \\\u003C 1.00 D.\n3. Subject must be myopic and require lens correction from -0.75 D to -4.00 D, at screening, in each eye.\n4. Subject must have distance best-spectacle corrected visual acuity (BSCVA) by non-cycloplegic manifest refraction of +0.04 logMAR (20\u002F20 Snellen equivalent) or better in each eye.\n5. Subject and Parent or Guardian must be willing to participate in either the test or the comparator assignment.\n6. Subject agrees to wear the assigned contact lenses for a minimum of 10 hours per day, at least 6 days per week, for the duration of the 24-month study.\n7. Subject must have wearable and visually functioning eyeglasses.\n8. Subject must be in good general health according to their and parent's or guardian's knowledge\n\nExclusion Criteria:\n\n1. Subject has previously worn, or currently wears rigid gas permeable contact lenses, including orthokeratology lenses.\n2. Current or prior use of bifocals, progressive addition lenses, multifocal soft contact lenses, atropine, pirenzepine or ANY other myopia control treatment.\n3. Subject appears to exhibit poor personal hygiene (that in the Investigator's opinion might prevent safe contact lens wear).\n4. Per oral inquiry from parents\u002Fguardian, the subject was born earlier than 30 weeks or weighed less than 1,500 g at birth.\n5. Prior strabismus, intraocular, or refractive surgery.\n6. Subject using any systemic or local eye medication that interfere with the wearing of corneal contact lenses, pupil size, adjustment or refractive status, or require the removal of lenses during the day\".\n7. A known allergy to fluorescein, benoxinate, proparacaine, or cyclopentolate.\n8. A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections.\n9. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction.\n10. Known ocular or systemic disease such as, but not limited to: anterior uveitis or iritis, episcleritis or scleritis, glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, or diabetes.\n11. At the discretion of the Investigator, any ocular, systemic or neuro developmental conditions that could influence refractive development such as, but not limited to: persistent pupillary membrane, vitreous hemorrhage, cataract, corneal scarring, ptosis, eyelid hemangiomas, Marfan's syndrome, Down syndrome, Ehlers-Danlos syndrome, Stickler syndrome, ocular albinism, retinopathy of prematurity. Subjects with trichiasis, that in the Investigator's judgement does not interfere with contact lens wear, are eligible for this study.\n12. Keratoconus or an irregular cornea.\n13. Subjects with any Grade 2 or greater finding during the slit lamp examination, or subjects with any scar or neovascularization within the central 6 mm of the cornea, or subjects with corneal infiltrates, of ANY GRADE.\n14. Subjects with any \"present\" finding during the slit lamp examination (biomicroscopy) that, in the investigator's judgment, interferes with contact lens wear. Subjects with minor peripheral corneal scarring (that does not extend into the central area), that in the Investigator's judgment does not interfere with contact lens wear, are eligible for this study.\n15. The Investigator for any reason considers that it is not in the best interest of the Subject to participate in the study.\n16. Subjects participating in any drug clinical investigation within 4 weeks or device clinical investigation within 2 weeks prior to entry into this study (Screening\u002FDispensing Visit) and\u002For planning to do so during the period of study participation.\n17. Immediate family or close relative is a member of site study team members","8 Years","12 Years",{"count":157,"type":20},418,[72],[139],{"date":142,"type":30},{"date":162,"type":30},"2024-03-29",{"date":164,"type":20},"2027-01-31",{"name":36,"class":37},11,""]